Friedrich SW - Search Results

1

A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system.

Bateman RJ, Siemers ER, Mawuenyega KG, Wen G, Browning KR, Sigurdson WC, Yarasheski KE, Friedrich SW, Demattos RB, May PC, Paul SM, Holtzman DM. Bateman RJ, et al. Among authors: friedrich sw. Ann Neurol. 2009 Jul;66(1):48-54. doi: 10.1002/ana.21623. Ann Neurol. 2009. PMID: 19360898 Free PMC article. Clinical Trial.

2

Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase.

Siemers ER, Dean RA, Friedrich S, Ferguson-Sells L, Gonzales C, Farlow MR, May PC. Siemers ER, et al. Clin Neuropharmacol. 2007 Nov-Dec;30(6):317-25. doi: 10.1097/WNF.0b013e31805b7660. Clin Neuropharmacol. 2007. PMID: 18090456 Clinical Trial.

3

Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease.

Siemers ER, Friedrich S, Dean RA, Gonzales CR, Farlow MR, Paul SM, Demattos RB. Siemers ER, et al. Clin Neuropharmacol. 2010 Mar-Apr;33(2):67-73. doi: 10.1097/WNF.0b013e3181cb577a. Clin Neuropharmacol. 2010. PMID: 20375655 Clinical Trial.

4

Safety and biomarker effects of solanezumab in patients with Alzheimer's disease.

Farlow M, Arnold SE, van Dyck CH, Aisen PS, Snider BJ, Porsteinsson AP, Friedrich S, Dean RA, Gonzales C, Sethuraman G, DeMattos RB, Mohs R, Paul SM, Siemers ER. Farlow M, et al. Alzheimers Dement. 2012 Jul;8(4):261-71. doi: 10.1016/j.jalz.2011.09.224. Epub 2012 Jun 5. Alzheimers Dement. 2012. PMID: 22672770 Clinical Trial.

5

Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor.

May PC, Dean RA, Lowe SL, Martenyi F, Sheehan SM, Boggs LN, Monk SA, Mathes BM, Mergott DJ, Watson BM, Stout SL, Timm DE, Smith Labell E, Gonzales CR, Nakano M, Jhee SS, Yen M, Ereshefsky L, Lindstrom TD, Calligaro DO, Cocke PJ, Greg Hall D, Friedrich S, Citron M, Audia JE. May PC, et al. J Neurosci. 2011 Nov 16;31(46):16507-16. doi: 10.1523/JNEUROSCI.3647-11.2011. J Neurosci. 2011. PMID: 22090477 Free PMC article. Clinical Trial.

6

Comparison of pharmacokinetics, pharmacodynamics, safety, and tolerability of the amyloid β monoclonal antibody solanezumab in Japanese and white patients with mild to moderate alzheimer disease.

Uenaka K, Nakano M, Willis BA, Friedrich S, Ferguson-Sells L, Dean RA, Ieiri I, Siemers ER. Uenaka K, et al. Clin Neuropharmacol. 2012 Jan-Feb;35(1):25-9. doi: 10.1097/WNF.0b013e31823a13d3. Clin Neuropharmacol. 2012. PMID: 22134132 Clinical Trial.

7

Sustained levels of antibodies against Aβ in amyloid-rich regions of the CNS following intravenous dosing in human APP transgenic mice.

Bard F, Fox M, Friedrich S, Seubert P, Schenk D, Kinney GG, Yednock T. Bard F, et al. Exp Neurol. 2012 Nov;238(1):38-43. doi: 10.1016/j.expneurol.2012.07.022. Epub 2012 Aug 7. Exp Neurol. 2012. PMID: 22892246

8

The effects on metabolic clearance when administering a potent CYP3A autoinducer with the prototypic CYP3A inhibitor, ketoconazole.

Ayan-Oshodi MA, Willis BA, Annes WF, Lowe SL, Friedrich S, de la Peña A, Zhang W, Brown T, Wise SD, Hall SD. Ayan-Oshodi MA, et al. Drug Metab Dispos. 2012 Oct;40(10):1945-52. doi: 10.1124/dmd.112.046060. Epub 2012 Jul 12. Drug Metab Dispos. 2012. PMID: 22789530 Clinical Trial.

9

Semagacestat pharmacokinetics are not significantly affected by formulation, food, or time of dosing in healthy participants.

Willis BA, Zhang W, Ayan-Oshodi M, Lowe SL, Annes WF, Sirois PJ, Friedrich S, de la Peña A. Willis BA, et al. J Clin Pharmacol. 2012 Jun;52(6):904-13. doi: 10.1177/0091270011407195. Epub 2011 Jul 1. J Clin Pharmacol. 2012. PMID: 21724950 Clinical Trial.

10

Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis.

Sandborn WJ, Ferrante M, Bhandari BR, Berliba E, Hibi T, D'Haens GR, Tuttle JL, Krueger K, Friedrich S, Durante M, Arora V, Naegeli AN, Schmitz J, Feagan BG. Sandborn WJ, et al. Clin Gastroenterol Hepatol. 2022 Jan;20(1):105-115.e14. doi: 10.1016/j.cgh.2020.09.028. Epub 2020 Sep 18. Clin Gastroenterol Hepatol. 2022. PMID: 32950748 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

27 results

Search Page

Filters